Extended Data Table 2 Serious adverse events by System Organ Class and Preferred Term

From: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial

  1. Preferred terms were defined according to the Medical Dictionary for Regulatory Activities terminology version 26.0, coded for all adverse events during the study.
Back to article page